Sign up for Breaking News Email Alerts

About Cell Therapy Pharmaceuticals ShareThis Contact Us


Press Releases

Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072006

2011 Archives

12/27/2011
Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
First Neuroregenerative Compound Tested In Depression
11/23/2011
First Patient Dosed in Cervical Region in Neuralstem ALS Stem Cell Trial
11/14/2011
Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11/09/2011
Neuralstem Reports Third Quarter Financial Results and Provides Business and Clinical Update
10/27/2011
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
10/24/2011
Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
10/12/2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
10/04/2011
Neuralstem Receives Patent Allowance For Compounds That Effect Neuronal Growth
09/27/2011
Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
09/12/2011
Neuralstem President and CEO to Update Ongoing ALS Trial at 2011 Rodman & Renshaw Annual Healthcare Conference
Live Webcast to Air on Tuesday, September 13, at 10:50 a.m. EDT
09/01/2011
Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
08/10/2011
Neuralstem Reports Second Quarter Financial Results and Provides Business and Clinical Update
08/03/2011
Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
07/21/2011
Neuralstem Receives Russian Patent for Stem Cell Transplantation to Treat Neurodegenerative Conditions
07/14/2011
Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
06/20/2011
Neuralstem Updates NSI-189 Major Depression Trial
Advancing to Final Phase Ia Cohort
06/14/2011
Neuralstem Updates ALS Clinical Trial Progress
APPROVED BY SAFETY MONITORING BOARD TO MOVE TO CERVICAL TRANSPLANTATIONS
06/07/2011
Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan
05/10/2011
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
04/20/2011
Neuralstem Signs Memorandum of Understanding for Ischemic Stroke Program in China
04/12/2011
Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
04/06/2011
Neuralstem ALS Trial in Multiple Presentations at Upcoming American Academy of Neurology Meeting
PRINCIPAL INVESTIGATOR, DR. EVA FELDMAN, TO PRESENT SAFETY DATA
03/16/2011
Neuralstem Announces 2010 Financial Results, Provides Update
03/03/2011
Neuralstem CEO and President to Present at 31st Annual Cowen Health Care Conference
03/01/2011
Neuralstem Announces First Subject Dosed in NSI-189 Safety Testing Toward Major Depressive Disorder Trial
1-25      26-29
 

print rss

Privacy and Terms ©Neuralstem, Inc. 2016

Information for Investors

ShareThis Copy and Paste